Sr. Director, National Payer Accounts

Overview

 

The Senior Director, National Payer Accounts is responsible for driving profitable patient access with the national payer organizations and their largest downstream regional account clients. Supporting the strategy of the Market Access team with the creation and execution of resources for the payer audience and patient services hub.  Collaborating with leaders in market access, therapeutic areas, insight, access strategy, finance, and medical affairs to align approaches to our largest customers. The Senior Director, National Payer Accounts will engage with key payer customers to develop relationships, secure medical and pharmacy policies that maximize patient access and ensure that the clinical and financial value of our products are fully understood. 

Additionally, the Senior Director, National Payer Accounts is primarily responsible for the implementation of strategies that maximize access and profit within each account.  Coordinating and leading our approach at each of their respective National Payer Accounts and specialty pharmacies, along with their largest regional clients the entire product portfolio (this position is focused on Anthem, Optum, UHC, Emisar, and Kaiser.  Responsible for their budget for and ensuring alignment with strategic and financial objectives of the overall business.  Collaborate closely with Therapeutic Areas, Market Access, Medical, Corporate Affairs and all internal stakeholders to maximize the value of our portfolio.

Responsibilities

Responsibilities

 

• Will execute a corporate negotiation strategy customized to the market access business environment, to help Stemline maximize its access and profitability.  Monitor and report on product performance.
• Monitor developments among government plans and private insurers to build strategies that will enable Stemline to anticipate and respond to market events.  
• Employs own expertise of the market access area, along with collected market data, to support and influence the development of the broader sales and marketing strategy.
• Individually maintain and continue to build strong, networked relationships throughout customer organizations, and develop/strengthen key relationships with account senior management and decision makers. 
• Troubleshoot particularly challenging opportunities with National Account customers. 
• Proactively resolve and respond to identified issues and challenges at accounts. 
• Demonstrate the value of our products, services and the Stemline organization.  Manage the interactions of executive-to-executive meetings
• Responsible for the development and implementation of major customer initiatives. Facilitates communication with field personnel and leadership
• Provide education, coaching and situational leadership to field colleagues on customer strategies and market trends.
• Responsible for the development of the account plan and the overall account strategy to include all stakeholders while working collaboratively to match customer's needs and expectations with internal Stemline capabilities (e.g., Medical, Finance, Marketing, R&D, Outcomes Research).
• Participate in Business reviews as a subject matter expert on assigned accounts.
• Represent Stemline at Key National Conferences and Congress (PCMA, AMCP, Asembia, Magellan, AHIP, etc.)

Qualifications

Skills/Knowledge

• Bachelor’s Degree in Sciences, Marketing, or Business
• 10+ years in pharmaceutical industry
• 5+ years work experience within various areas of market access
• Thorough understanding of market dynamics across multiple therapeutic areas (oncology/hematology preferred) and across various business segments
• Demonstrated success in account management (national account experience with UHC, Optum, and Emisar preferred) with a demonstrated proficiency for contracting and marketing.
• History of performance in achieving business objectives
• Ability to form and sustain relationships across a customer organization. 
• Ability to facilitate, integrate, and deliver multiple corporate resources to customers. 
• Contracting/negotiations expertise/training. 
• Excellent collaboration, presentation and communication skills (both written and oral) required.
• Strong organizational skills, attention to detail, ability to prioritize and meet deadlines.
• Team player and self-starter with a constructive attitude.
• Must have a “roll-up their sleeves” work style understanding both tactical and strategic work are requirements.
• Ability to travel up to 50%

Base Salary Range of $240,000-$280,000.  Menarini Stemline offers generous compensation and benefits packages,  including Short- and Long-Term Incentive Programs,  Fidelity 401(k) (with 6% company match), Anthem Premier PPO and HDHP insurance plans, Company paid Basic Life & AD&D insurance and pre-tax FSA/HSA programs.

Menarini Stemline is committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran.

 

About us:

 

Reasonable accommodations may be made to enable qualified individuals with disabilities to perform the essential functions.

 

Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.

 

The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.

Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.

 

Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and solid tumours. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF).

 

Additionally, Menarini received exclusive rights to commercialise Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines.

 

Menarini entered into a global licence agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023.

 

It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business.